734P Neutrophil-lymphocyte ratio predicts survival in platinum-resistant ovarian cancer patients treated with olaparib and pegylated liposomal doxorubicin (PLD): Stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601

734P Neutrophil-lymphocyte ratio predicts survival in platinum-resistant ovarian cancer patients treated with olaparib and pegylated liposomal doxorubicin (PLD): Stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601

Saved in:
Bibliographic Details
Published in:Annals of oncology Vol. 32; p. S735
Main Authors: Fidalgo, J.A. Perez, Cortés, A., García, Y., Iglesias, M., Sarmiento, U. Bohn, García, E. Calvo, Manso, L., Santaballa, A., Oaknin, A., Redondo, A., Rubio, M.J., González-Martín, A.
Format: Journal Article
Language:English
Published: Elsevier Ltd 01-09-2021
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0923-7534
1569-8041
DOI:10.1016/j.annonc.2021.08.1177